Apnimed Prices IPO at $16 Per Share to Raise $192 Million

Apnimed, Inc., a clinical-stage pharmaceutical company, has priced its initial public offering of 12 million shares of common stock at $16.00 per share. The offering is expected to generate gross proceeds of $192 million before underwriting discounts and commissions, according to a company press release.

Offering Details

The Cambridge, Massachusetts-based company's stock is expected to begin trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol APMD. The offering is anticipated to close on or about August 3, 2026, subject to customary closing conditions.

Key details of the offering include:

• Shares Offered: 12 million shares of common stock.
• IPO Price: $16.00 per share.
• Gross Proceeds: Approximately $192 million.

Apnimed has also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares at the initial public offering price.

Pipeline and Use of Proceeds

Ad

The capital raised arrives as Apnimed advances its lead product candidate, AD109, an oral therapy for obstructive sleep apnea. The company has completed two Phase 3 clinical trials for the drug, which is designed to improve oxygenation during sleep.

The U.S. Food and Drug Administration (FDA) has accepted Apnimed's New Drug Application for AD109. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027, to make its decision on the drug's approval. The proceeds from the IPO are expected to support the company's operations through this key regulatory milestone and potential commercial launch.

Market Context

For investors, the IPO offers an opportunity to invest in a late-stage biopharmaceutical company with a clear, near-term catalyst. The successful completion of the offering will provide Apnimed with significant capital to transition from a clinical to a commercial-stage entity if AD109 secures regulatory approval.

BofA Securities, Evercore ISI, Cantor, and LifeSci Capital are acting as the joint book-running managers for the transaction.